Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masayuki Ikeda

Showing results (1-10 of 171) with videos related to

Pageof 18
Sort By:
The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry|July 24, 2004
Calcium dynamics and circadian rhythms in suprachiasmatic nucleus neuronsMasayuki Ikeda
Rinsho Shinkeigaku = Clinical Neurology|May 30, 2017
Delays in clinical development of neurological drugs in JapanMasayuki Ikeda
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 5, 2014
Bmal1 is an essential regulator for circadian cytosolic Ca²⁺ rhythms in suprachiasmatic nucleus neuronsMasayuki Ikeda, Masaaki Ikeda
Journal of Pharmaceutical Policy and Practice|June 1, 2021
Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)Rumiko Shimazawa, Masayuki Ikeda
Personalized Medicine|May 12, 2018
Overcoming regulatory challenges in the development of companion diagnostics for monitoring and safetyRumiko Shimazawa, Masayuki Ikeda
British Journal of Clinical Pharmacology|March 11, 2021
Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: A tripartite comparisonRumiko Shimazawa, Masayuki Ikeda
Clinical Therapeutics|October 6, 2012
Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applicationsRumiko Shimazawa, Masayuki Ikeda
European Neurology|May 31, 2002
Longitudinal changes in brain CT scans and development of dementia in Down's syndromeMasayuki Ikeda, Yukio Arai
Internal Medicine (Tokyo, Japan)|August 2, 2011
Delays in neurological drug development in JapanRumiko Shimazawa, Masayuki Ikeda
Journal of Pharmaceutical Policy and Practice|January 11, 2017
Approval status and evidence for WHO essential medicines for children in the United States, United Kingdom, and Japan: a cross-sectional studyRumiko Shimazawa, Masayuki Ikeda
Pageof 18

Showing results (1-10 of 171) with videos related to

Sort By:
Pageof 18
The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry|July 24, 2004
Calcium dynamics and circadian rhythms in suprachiasmatic nucleus neuronsMasayuki Ikeda
Rinsho Shinkeigaku = Clinical Neurology|May 30, 2017
Delays in clinical development of neurological drugs in JapanMasayuki Ikeda
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 5, 2014
Bmal1 is an essential regulator for circadian cytosolic Ca²⁺ rhythms in suprachiasmatic nucleus neuronsMasayuki Ikeda, Masaaki Ikeda
Journal of Pharmaceutical Policy and Practice|June 1, 2021
Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)Rumiko Shimazawa, Masayuki Ikeda
Personalized Medicine|May 12, 2018
Overcoming regulatory challenges in the development of companion diagnostics for monitoring and safetyRumiko Shimazawa, Masayuki Ikeda
British Journal of Clinical Pharmacology|March 11, 2021
Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: A tripartite comparisonRumiko Shimazawa, Masayuki Ikeda
Clinical Therapeutics|October 6, 2012
Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applicationsRumiko Shimazawa, Masayuki Ikeda
European Neurology|May 31, 2002
Longitudinal changes in brain CT scans and development of dementia in Down's syndromeMasayuki Ikeda, Yukio Arai
Internal Medicine (Tokyo, Japan)|August 2, 2011
Delays in neurological drug development in JapanRumiko Shimazawa, Masayuki Ikeda
Journal of Pharmaceutical Policy and Practice|January 11, 2017
Approval status and evidence for WHO essential medicines for children in the United States, United Kingdom, and Japan: a cross-sectional studyRumiko Shimazawa, Masayuki Ikeda
Pageof 18